I suspect that a number of us took a look at the JVs and bought in. Like you, I was never interested. However, many of the projects in preclinical and early clinical look to be of interest...... the business plan was maturing, IMO, at exactly the same time that (1) the alzheimer's project hit murky water and, and (2) Jesse Eisinger et al. did their act.
Looks like a great complement to other stuff I like. No farm bet. A tad.
To any company that lagged in biotech, has resources, and wants competitive leverage that will blossom 2006-2010, it's worth better than $20, IMO. It might be perfect for a med devices company that wants a presence in biologicals or specialty pharmaceuticals? It could also look good to an Amgen. Nobody would consider it possible, after Immunex. I think that they'd be brilliant to make it happen, in any event. But, it's probably out.
There are many scenarios that fit. We'll see how it plays out. It won't be boring. Geaney et al. were doing a brilliant job. The crew at Athena has really had a big impact on biotech, as it turns out. |
